Adjuvant effects of chemotherapeutics and metformin on MFE-319 endometrial carcinoma cell line

Simple item page
dc.contributor.authorAydemir I.
dc.contributor.authorUluer E.T.
dc.contributor.authorKorkmaz O.
dc.contributor.authorTuglu M.I.
dc.contributor.authorInan S.
dc.date.accessioned2024-07-22T08:07:17Z
dc.date.available2024-07-22T08:07:17Z
dc.date.issued2020
dc.description.abstractWe aimed to investigate the cytotoxicity of Metformin, Cisplatin, and Paclitaxel on MFE-319 endometrial carcinoma cell line using 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and immunocytochemistry assays. Half maximal inhibitory concentration (IC50) doses of three drugs alone and in the dual combinations were applied to the cells. Immunocytochemical method was performed for the cell survival and for phosphatidylinositol 3-kinase (PI3K), phosphorylated extracellular regulated kinases (pErk)-1/2, Akt-1, phosphorylated Akt (pAkt)-1/2/3 cell growth markers and angiogenic vascular endothelial growth factor (VEGF). Immunoreactivities were evaluated using H-score and analyzed using the one-way analysis of variance (ANOVA) test for statistics. It was found that these drugs caused a decrease in the immunoreactivities of these markers. Particularly, dual combination of Paclitaxel and Cisplatin decreased the immunoreactivities of PI3K, pErk-1/2, Akt-1, and pAkt-1/2/3. Cisplatin and Paclitaxel were more effective than Metformin; on the other hand, Metformin has been shown to enhance the efficacy of these two drugs. In vitro or in vivo further studies are needed to investigate the efficacy of these three drugs via PI3K/Akt signal pathway. © 2020, Editura Academiei Romane. All rights reserved.
dc.identifier.DOI-ID10.47162/RJME.61.3.09
dc.identifier.issn12200522
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13899
dc.language.isoEnglish
dc.publisherEditura Academiei Romane
dc.rightsAll Open Access; Bronze Open Access; Green Open Access
dc.subjectCell Line
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectEndometrial Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectMetformin
dc.subjectPhosphatidylinositol 3-Kinases
dc.subjectProto-Oncogene Proteins c-akt
dc.subjectVascular Endothelial Growth Factor A
dc.subjectmetformin
dc.subjectphosphatidylinositol 3 kinase
dc.subjectprotein kinase B
dc.subjectvasculotropin A
dc.subjectcell line
dc.subjectcell proliferation
dc.subjectendometrium tumor
dc.subjectfemale
dc.subjecthuman
dc.subjecttumor cell line
dc.titleAdjuvant effects of chemotherapeutics and metformin on MFE-319 endometrial carcinoma cell line
dc.typeArticle

Files

Collections

Scopus Koleksiyonu